Loading clinical trials...
Loading clinical trials...
An Open, Single Dose Escalation Study Followed by a Multiple Dose Extension of Anti-EGF Receptor Human Monoclonal Antibody (Zalutumumab) in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Conditions
Interventions
Zalutumumab
Locations
5
Denmark
Århus Kommunehospital
Århus C, Denmark
Rigshospitalet
Copenhagen Ø, Denmark
Odense Universitetshospital
Odense, Denmark
Universitets Sjukhuset i Lund
Lund, Sweden
Uppsala Akademiska Sjukhus
Uppsala, Sweden
Start Date
December 1, 2003
Primary Completion Date
January 12, 2005
Completion Date
January 12, 2005
Last Updated
June 28, 2023
NCT06998069
NCT06912087
NCT06303180
NCT05418842
NCT03914378
NCT06003231
Lead Sponsor
Genmab
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions